Lifeboat Foundation

Innovative vaccine uses another virus to present two genes from the novel coronavirus.

A duo of preclinical studies recently demonstrated a new way to ferry medicines past the blood-brain barrier. And other research is on the way.

A personal, handheld device emitting high-intensity ultraviolet light to disinfect areas by killing the novel coronavirus is now feasible, according to researchers at Penn State, the University of Minnesota and two Japanese universities.

There are two commonly employed methods to sanitize and disinfect areas from bacteria and viruses—chemicals or ultraviolet radiation exposure. The UV radiation is in the 200 to 300 nanometer range and known to destroy the virus, making the virus incapable of reproducing and infecting. Widespread adoption of this efficient UV approach is much in demand during the current pandemic, but it requires UV radiation sources that emit sufficiently high doses of UV light. While devices with these high doses currently exist, the UV radiation source is typically an expensive mercury-containing gas discharge lamp, which requires high power, has a relatively short lifetime, and is bulky.

The solution is to develop high-performance, UV light emitting diodes, which would be far more portable, long-lasting, energy efficient and environmentally benign. While these LEDs exist, applying a current to them for light emission is complicated by the fact that the electrode material also has to be transparent to UV light.

As countries around the world begin lifting pandemic lockdowns, researchers are entering a new phase of work — donning masks with their lab coats, staggering hours in laboratory spaces and taking shifts on shared instruments. Some universities have created detailed plans to track and test staff, and many have limited the capacity of indoor spaces and the flow of people through hallways and entrances. For others, post-lockdown plans are still taking shape. And whereas some universities have worked in lockstep with governments to formulate safety plans, others have charted their own paths.

As scientists around the world return to work, they’re encountering new safety rules and awkward restrictions — and sometimes writing the protocols themselves.

“What you see in these diseases of aging is often the sort of unintended consequences of a system that was absolutely awesome for the young, at the expense of the old.” — Ned David.

Once considered an unimportant curiosity, Z-DNA is now recognized to provide an on-the-fly mechanism to regulate how an RNA transcript is edited.

The Infant Gut Microbiome and Probiotics that Work.

Indian start-up Nugenics Research to commercialise “Elixir” after showing 54% age reversal in animal study.

KINSHASA (Reuters) — Authorities in Congo announced a new Ebola outbreak in the western city of Mbandaka on Monday, adding to another epidemic of the virus that has raged in the east since 2018.

Eli Lilly and AbCellera dosed the first patients in a Phase I study of a potential antibody treatment for COVID-19. The two companies were able to get their antibody candidate into the clinic within two months of announcing their collaboration in response to the global pandemic.

The announcement was made a day after it was announced that more than 6 million people across the globe have been infected with the virus, including 1.79 million in the United States. COVID-19 has been responsible for the deaths of more than 372,000 people, with nearly one-third (104,383) in the U.S.

Patients were dosed with LY-CoV555, a neutralizing IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, which should neutralize the virus, and potentially prevent and treat COVID-19. Because it’s an antibody derived from the blood of a recovered patient, Eli Lilly said LY-CoV555 is the first potential new medicine specifically designed to attack SARS-CoV-2, the virus that causes COVID-19.